Company Encyclopedia
View More
name
WIT DYNE
000915.SZ
Shandong Wit Dyne Health Co.,Ltd. engages in the pharmaceutical business in China. Its medical products include azithromycin granules, licorice zinc granules, compound calcium carbonate, vitamin AD drops, epalrestat tablets, valsartan hydrochlorothiazide gel, roxithromycin, rosiglitazone tartrate tablets, and glimepiride tablets. The company also provides dextran iron granules, oral rehydration salt powder, montmorillonite powder, azithromycin granules, rifaximin dry suspension, and succinate capsules.
3.157 T
000915.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking43/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE19.89%A
    • Profit Margin23.66%A
    • Gross Margin81.24%A
  • Growth ScoreB
    • Revenue YoY10.06%B
    • Net Profit YoY13.95%C
    • Total Assets YoY4.56%C
    • Net Assets YoY2.63%C
  • Cash ScoreC
    • Cash Flow Margin422.60%C
    • OCF YoY10.06%B
  • Operating ScoreC
    • Turnover0.5C
  • Debt ScoreA
    • Gearing Ratio11.99%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    WIT DYNE released its performance for the first three quarters, with a net profit attributable to the parent company of 408 million yuan, a year-on-year increase of 11.67%

    According to the Zhitong Finance APP, WIT DYNE released its Q3 2025 report. In the first three quarters, the company achieved operating revenue of 1.603 billion yuan, a year-on-year increase of 16.30%. The net profit attributable to shareholders of the listed company was 408 million yuan, a year-on-year increase of 11.67%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 400 million yuan, a year-on-year increase of 15.80%

    Zhitong·
    SZ
    000915
    -0.54%
    Zhitong·
    SZ
    000915
    -0.54%

    WIT DYNE: The net profit for the third quarter was 70.5981 million yuan, a year-on-year increase of 110.42%

    WIT DYNE announced that its revenue for the third quarter was 432 million yuan, a year-on-year increase of 93.28%; net profit was 70.5981 million yuan, a year-on-year increase of 110.42%. Revenue for the first three quarters was 1.603 billion yuan, a year-on-year increase of 16.30%; net profit was 408 million yuan, a year-on-year increase of 11.67%

    Zhitong·
    SZ
    000915
    -0.54%
    Zhitong·
    SZ
    000915
    -0.54%

    WIT DYNE: A cash dividend of 5 yuan for every 10 shares

    WIT DYNE announced that the interim dividend for 2025 will be based on a total share capital of 234 million shares as of June 30, 2025, distributing a cash dividend of 5 yuan for every 10 shares to all shareholders of the company, without increasing share capital from capital reserves or issuing bonus shares. The actual cash dividend amount for the first half of 2025 will be 117 million yuan. The equity registration date is October 16, 2025, and the ex-dividend date is October 17, 2025

    Zhitong·
    SZ
    000915
    -0.54%
    Zhitong·
    SZ
    000915
    -0.54%

    WIT DYNE released its performance for the first half of the year, with a net profit attributable to the parent company of 337 million yuan, an increase of 1.69%

    WIT DYNE released its semi-annual report for 2025, with operating revenue of 1.17 billion yuan, a year-on-year increase of 1.39%; net profit attributable to shareholders of 337 million yuan, a year-on-year increase of 1.69%. The net profit after deducting non-recurring gains and losses was 332 million yuan, a year-on-year increase of 4.31%. The basic earnings per share were 1.44 yuan, and it plans to distribute a cash dividend of 5 yuan (including tax) for every 10 shares to all shareholders

    Zhitong·
    SZ
    000915
    -0.54%
    Zhitong·
    SZ
    000915
    -0.54%

    WIT DYNE subsidiary signs general distribution contract for melatonin granules (Manlejing)

    WIT DYNE's subsidiary Beijing Dainkangjian Pharmaceutical Co., Ltd. has signed an exclusive general distribution agreement for melatonin granules (Manlejing®) with Japan's NOBORI Pharmaceutical Co., Ltd. According to the agreement, Dainkangjian will become the exclusive general distributor of the product in mainland China, responsible for the import, marketing, and sales of the product

    Zhitong·
    SZ
    000915
    -0.54%
    Zhitong·
    SZ
    000915
    -0.54%
    © 2025 Longbridge｜Disclaimer